AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04902534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naoqingzhiming Tablets (contains echinacoside 180mg)
Description: Single dose escalation and multiple dose escalation
Study NCT04902534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of Naoqingzhiming Tablets (without echinacoside)
Description: Single dose escalation and multiple dose escalation
Study NCT02581358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scolioscan (Ultrasound imaging system)
Description: To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
Study NCT03411850 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Orencia
Description: FDA approved biologic
Study NCT03411850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04080869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retinyl palmitate
Description: topical retinyl palmitate loaded ethosomes
Study NCT04080869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: topical tretinoin
Study NCT04465123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone or hydrochlorothiazide
Description: Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels >4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours.
Study NCT04465123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels >4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours.
Study NCT01071096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm.
Study NCT01071096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm.
Study NCT04520828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural repositioning
Description: The 10-min transdisciplinary intervention aimed (1) to facilitate and activate axial extension during standing and then during sitting; (2) to actively mobilize the trunk, cervical spine, and pelvic and shoulder girdles during standing and then during sitting; and (3) to adjust the seated position, as needed, with supports to ensure its maintenance throughout the experiment. Cushion, balls, boxes, or rolls were used to stabilize the final seated position.
Study NCT05265143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bolus/intermittant feeding
Description: sequential randomization
Study NCT03317574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
Study NCT03317574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
Study NCT02640066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Study NCT00511953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin Extended Release tablets
Description: 1800mg
Study NCT00511953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin Extended Release tablets
Description: 1800mg
Study NCT00511953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 1800mg
Study NCT00511953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: 1800mg
Study NCT03427541 — intervention group
Intervention type: PROCEDURE
Intervention: Surgeries
Description: Surgeries
Study NCT01978158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: LPS is used to elicit an inflammatory response in all subjects
Study NCT01978158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: LPS is used to elicit an inflammatory response in all subjects
Study NCT01922778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D\&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter.
Study NCT01372371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
Study NCT01372371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin and Gentamycin
Description: 1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
Study NCT01372371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: 1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
Study NCT01788982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib should be administered orally at a dose of 200 mg twice daily.
Study NCT01788982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nintedanib
Description: Nintedanib should be administered orally at a dose of 200 mg twice daily.
Study NCT01788982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00131677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir disoproxil fumarate
Description: study product taken daily
Study NCT00131677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: study product taken daily
Study NCT05436886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurogabin (Gabapentin) 400 mg capsule
Description: All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
Study NCT03009994 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Repair of uterine incision
Study NCT03009994 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exteriorization of the uterus
Study NCT03009994 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non exteriorization of the uterus
Study NCT02945098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
Study NCT02945098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Kinesio Taping
Description: Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
Study NCT00779636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine 10 mg daily x 28 days
Study NCT00779636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily x 28 days
Study NCT00313443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat tissue needle aspiration
Description: Small fat tissue sampling performed by needle aspiration.
Study NCT01231802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eniluracil
Description: Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, \& 15
Study NCT01231802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, \& 16
Study NCT01231802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17
Study NCT00821366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ARV peer adherence support (PAS)
Description: Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
Study NCT00821366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional support
Description: Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
Study NCT00821366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARV treatment
Description: Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
Study NCT05436886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurogabin (Gabapentin) 400 mg capsule
Description: All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
Study NCT05436886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parketin (Gabapentin) 400 mg capsule
Description: All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
Study NCT05436886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parketin (Gabapentin) 400 mg capsule
Description: All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
Study NCT02262884 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SurgiQuest AirSeal Insufflation System (AIS)
Description: Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
Study NCT02262884 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Insufflation System (CIS)
Description: Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
Study NCT03687138 — intervention group
Intervention type: OTHER
Intervention: 24h urin sample
Description: The samples will analyzed by proteomic techniques
Study NCT01314976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents.
Study NCT01314976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis.
Study NCT00274768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
Study NCT04453904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sequential radiochemotherapy in a sanwich mode
Description: Patients will randomized into two different modalities of radiochemotherapy.
Study NCT04453904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sequential radiochemotherapy in a sanwich mode
Description: Patients will randomized into two different modalities of radiochemotherapy.
Study NCT00871377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn oil (n-6 fatty acids)
Study NCT00871377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Fish Oil
Description: n-3 fatty acids, 1060 mg EPA + DHA
Study NCT00871377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Fish Oil
Description: n-3 fatty acids, 2160 mg EPA + DHA
Study NCT00975429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
Study NCT00975429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
Study NCT02152358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciclovir
Description: Intravenous 15 mg/kg/d during 14 days
Study NCT02152358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: intravenous 10 mg/kg/d for 14 days
Study NCT02152358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04579796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound exam
Description: An abdominal ultrasound exam to assess the placenta implantation site.
Study NCT04579796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopy diagnostic
Description: Diagnostic hysteroscopy to asses the placenta implantation site.
Study NCT04781569 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: Health-related personal data such as year of birth, sex, Body Mass Index (BMI), infection classification, concomitant infections, comorbidities according to medical chart, standard diagnostic markers (CRP, blood differential plots, creatinine, ...), medication, treatment start, treatment end and discharge from hospital will be collected.
Study NCT04781569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: 2 blood drawing events (in total 22.5 ml) will be performed in the patient. 1 blood drawing events will be performed in the healthy proband.
Study NCT04781569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: nose swabs
Description: 2 nose swabs will be taken in the patient. 1 nose swab will be performed in the healthy proband.
Study NCT04781569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative tissue samples
Description: Intraoperative tissue samples from the site of infection during surgery will be taken in the patient.
Study NCT01590394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Large plastic biliary stent
Description: Stent placement for bile duct obstruction.
Study NCT03050216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total
Study NCT03796234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary and physiotherapy
Description: 3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
Study NCT01231802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
Study NCT03796234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
Study NCT03659760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Isolated
Description: Eyes closed with patch and ears plugged between 24:00-06:00
Study NCT02703701 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physician at triage
Description: A physician embedded at triage
Study NCT02703701 — intervention group
Intervention type: OTHER
Intervention: Usual Care
Description: No physician at triage
Study NCT01093755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexlansoprazole
Description: Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
Study NCT01093755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Escalating doses of omeprazole (20-60 mg/day) for 6 months
Study NCT03388996 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: microbiomes
Description: 16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
Study NCT03497260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
Study NCT03497260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain water
Description: Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
Study NCT01429350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
Description: 0.9mg/kg to a maximum of 90mg
Study NCT01429350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penumbra System
Description: The Penumbra System is an aspiration based mechanical thrombectomy device
Study NCT00716859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Timolol 0.5% dosed twice-daily
Study NCT00716859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost
Description: Latanoprost 0.005% ophthalmic solution dosed once-daily
Study NCT01130727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: green tea extract
Description: 1.21g of green tea extract (965 mg of flavonols)